Marthe Larsen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Marthe Larsen has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
- Solveig Hofvind
Norwegian Institute of Public Health
5 shared publications - Nataliia Moshina
Norwegian Institute of Public Health
4 shared publications - Edoardo Botteri
Cancer Registry of Norway, Oslo, Norway
2 shared publications - John Cairns
Department of Health Services Research and Policy, London School of Hygiene & Tropical Medicine, London, UK
2 shared publications - Lars Andreas Akslen
Centre for Cancer Biomarkers CCBIO, Department of Clinical Medicine University of Bergen Bergen Norway
2 shared publications - Ragnhild Sørum Falk
Research Support Services, Oslo University Hospital, Oslo, Norway
2 shared publications
Latest Publications
- Open Access
- 27 June 2025
- Published by Springer Nature in Quality of Life Research
- Vol. 34 (8) , 2427-2436
Correction: Quality of life among women with symptomatic, screen‑detected, and interval breast cancer, and for women without breast cancer: a retrospective cross‑sectional study from Norway
- 27 June 2025
- Published by Springer Nature in Quality of Life Research
- Vol. 34 (8) , 2427-2436
Open AccessCorrection: Quality of life among women with symptomatic, screen‑detected, and interval breast cancer, and for women without breast cancer: a retrospective cross‑sectional study from Norway
- Open Access
- 11 October 2023
- Published by Elsevier in Preventive Medicine
- Vol. 175, 107723
Prolonged screening interval due to the COVID-19 pandemic and its association with tumor characteristics and treatment; a register-based study from BreastScreen Norway
- 11 October 2023
- Published by Elsevier in Preventive Medicine
- Vol. 175, 107723
Open AccessProlonged screening interval due to the COVID-19 pandemic and its association with tumor characteristics and treatment; a register-based study from BreastScreen Norway
- Open Access
Personalized Breast Cancer Screening: A Risk Prediction Model Based on Women Attending BreastScreen Norway
Background: We aimed to develop and validate a model predicting breast cancer risk for women targeted by breast cancer screening. Method: This retrospective cohort study included 57,411 women screened at least once in BreastScreen Norway during the period from 2007 to 2019. The prediction model included information about age, mammographic density, family history of breast cancer, body mass index, age at menarche, alcohol consumption, exercise, pregnancy, hormone replacement therapy, and benign breast disease. We calculated a 4-year absolute breast cancer risk estimates for women and in risk groups by quartiles. The Bootstrap resampling method was used for internal validation of the model (E/O ratio). The area under the curve (AUC) was estimated with a 95% confidence interval (CI). Results: The 4-year predicted risk of breast cancer ranged from 0.22–7.33%, while 95% of the population had a risk of 0.55–2.31%. The thresholds for the quartiles of the risk groups, with 25% of the population in each group, were 0.82%, 1.10%, and 1.47%. Overall, the model slightly overestimated the risk with an E/O ratio of 1.10 (95% CI: 1.09–1.11) and the AUC was 62.6% (95% CI: 60.5–65.0%). Conclusions: This 4-year risk prediction model showed differences in the risk of breast cancer, supporting personalized screening for breast cancer in women aged 50–69 years.
Open AccessPersonalized Breast Cancer Screening: A Risk Prediction Model Based on Women Attending BreastScreen Norway
Background: We aimed to develop and validate a model predicting breast cancer risk for women targeted by breast cancer screening. Method: This retrospective cohort study included 57,411 women screened at least once in BreastScreen Norway during the period from 2007 to 2019. The prediction model included information about age, mammographic density, family history of breast cancer, body mass index, age at menarche, alcohol consumption, exercise, pregnancy, hormone replacement therapy, and benign breast disease. We calculated a 4-year absolute breast cancer risk estimates for women and in risk groups by quartiles. The Bootstrap resampling method was used for internal validation of the model (E/O ratio). The area under the curve (AUC) was estimated with a 95% confidence interval (CI). Results: The 4-year predicted risk of breast cancer ranged from 0.22–7.33%, while 95% of the population had a risk of 0.55–2.31%. The thresholds for the quartiles of the risk groups, with 25% of the population in each group, were 0.82%, 1.10%, and 1.47%. Overall, the model slightly overestimated the risk with an E/O ratio of 1.10 (95% CI: 1.09–1.11) and the AUC was 62.6% (95% CI: 60.5–65.0%). Conclusions: This 4-year risk prediction model showed differences in the risk of breast cancer, supporting personalized screening for breast cancer in women aged 50–69 years.
- 3 April 2022
- Published by Elsevier in Radiography
- Vol. 28 (3) , 772-778
Standardised or individualised X-ray tube angle for mediolateral oblique projection in digital mammography?
- 3 April 2022
- Published by Elsevier in Radiography
- Vol. 28 (3) , 772-778
Standardised or individualised X-ray tube angle for mediolateral oblique projection in digital mammography?
- Open Access
- 26 October 2021
- Published by Springer Nature in Quality of Life Research
- Vol. 31 (4) , 1057-1068
Quality of life among women with symptomatic, screen-detected, and interval breast cancer, and for women without breast cancer: a retrospective cross-sectional study from Norway
Purpose: Breast cancers detected at screening need less aggressive treatment compared to breast cancers detected due to symptoms. The evidence on the quality of life associated with screen-detected versus symptomatic breast cancer is sparse. This study aimed to compare quality of life among Norwegian women with symptomatic, screen-detected and interval breast cancer, and women without breast cancer and investigate quality adjusted life years (QALYs) for women with breast cancer from the third to 14th year since diagnosis. Methods: This retrospective cross-sectional study was focused on women aged 50 and older. A self-reported questionnaire including EQ-5D-5L was sent to 11,500 women. Multivariable median regression was used to analyze the association between quality of life score (visual analogue scale 0–100) and detection mode. Health utility values representing women’s health status were extracted from EQ-5D-5L. QALYs were estimated by summing up the health utility values for women stratified by detection mode for each year between the third and the 14th year since breast cancer diagnosis, assuming that all women would survive. Results: Adjusted regression analyses showed that women with screen-detected (n = 1206), interval cancer (n = 1005) and those without breast cancer (n = 1255) reported a higher median quality of life score using women with symptomatic cancer (n = 1021) as reference; 3.7 (95%CI 2.2–5.2), 2.3 (95%CI 0.7–3.8) and 4.8 (95%CI 3.3–6.4), respectively. Women with symptomatic, screen-detected and interval cancer would experience 9.5, 9.6 and 9.5 QALYs, respectively, between the third and the 14th year since diagnosis. Conclusion: Women with screen-detected or interval breast cancer reported better quality of life compared to women with symptomatic cancer. The findings add benefits of organized mammographic screening.
- 26 October 2021
- Published by Springer Nature in Quality of Life Research
- Vol. 31 (4) , 1057-1068
Open AccessQuality of life among women with symptomatic, screen-detected, and interval breast cancer, and for women without breast cancer: a retrospective cross-sectional study from Norway
Purpose: Breast cancers detected at screening need less aggressive treatment compared to breast cancers detected due to symptoms. The evidence on the quality of life associated with screen-detected versus symptomatic breast cancer is sparse. This study aimed to compare quality of life among Norwegian women with symptomatic, screen-detected and interval breast cancer, and women without breast cancer and investigate quality adjusted life years (QALYs) for women with breast cancer from the third to 14th year since diagnosis. Methods: This retrospective cross-sectional study was focused on women aged 50 and older. A self-reported questionnaire including EQ-5D-5L was sent to 11,500 women. Multivariable median regression was used to analyze the association between quality of life score (visual analogue scale 0–100) and detection mode. Health utility values representing women’s health status were extracted from EQ-5D-5L. QALYs were estimated by summing up the health utility values for women stratified by detection mode for each year between the third and the 14th year since breast cancer diagnosis, assuming that all women would survive. Results: Adjusted regression analyses showed that women with screen-detected (n = 1206), interval cancer (n = 1005) and those without breast cancer (n = 1255) reported a higher median quality of life score using women with symptomatic cancer (n = 1021) as reference; 3.7 (95%CI 2.2–5.2), 2.3 (95%CI 0.7–3.8) and 4.8 (95%CI 3.3–6.4), respectively. Women with symptomatic, screen-detected and interval cancer would experience 9.5, 9.6 and 9.5 QALYs, respectively, between the third and the 14th year since diagnosis. Conclusion: Women with screen-detected or interval breast cancer reported better quality of life compared to women with symptomatic cancer. The findings add benefits of organized mammographic screening.